Cancer in the News #10: Treatment options for HER2+ breast cancer, brain metastases, and TNBC

10th issue

This issue focuses on current/new western medicine treatment options for HER2+ breast cancer, brain metastases, and TNBC…

• Single Dose Radiotherapy as Effective as Conventional Therapy for Patients with Breast Cancer

“Early results of using single dose TARGIT-IORT during lumpectomy were promising, and the treatment was found to have advantages for the patient, such as convenience, reduced travel and personal costs, improved quality of life, and fewer side effects,” wrote the researchers.

My two cents: If less radiation can be just as effective as more radiation, than less is more, especially in light of side effects and toxicity.

• Practicing Oncologists Debate New Tactics for Brain Metastases in HER2+ Breast Cancer

“The conversation revolved around the primary and subgroup analysis of 3 studies, each of which included patients with brain metastases

• HER2CLIMB (NCT02614794) evaluated tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for patients with advanced unresectable or metastatic HER2-positive breast cancer who have received 1 or more prior anti–HER2-based regimens in the metastatic setting.1,2
• DESTINY-Breast01 (NCT03248492) assessed fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with unresectable or…